aim
review
evalu
efficaci
safeti
antibiot
agent
children
well
introduc
present
situat
antibiot
use
bacteri
coinfect
patient
evalu
risk
bia
includ
studi
synthes
result
use
qualit
synthesi
six
studi
met
inclus
criteria
five
studi
sar
show
overal
risk
death
one
studi
sar
patient
use
macrolid
quinolon
beta
lactamas
show
mean
durat
hospit
stay
day
respect
averag
durat
fever
day
respect
one
cohort
studi
mer
indic
macrolid
therapi
associ
signific
reduct
mortal
adjust
odd
ratio
confid
interv
ci
p
improv
merscov
rna
clearanc
adjust
hazard
ratio
hr
ci
p
accord
find
studi
proport
antibiot
use
rang
children
adult
despit
lack
etiolog
evid
commonli
use
antibiot
adult
quinolon
cephalosporin
macrolid
children
meropenem
linezolid
benefit
antibiot
agent
adult
sar
mer
question
absenc
bacteri
coinfect
evid
support
use
antibiot
agent
children
absenc
bacteri
coinfect
major
patient
receiv
intraven
antibiot
therapi
moreov
multipl
case
seri
cohort
studi
sar
patient
testifi
proport
patient
receiv
antibiot
agent
use
absenc
confirm
bacteri
coinfect
among
treat
combin
sever
antibiot
agent
use
antibiot
long
durat
combin
multipl
agent
show
efficaci
diseas
progress
also
caus
complic
potenti
fatal
secondari
infect
howev
author
argu
prophylact
use
antibiot
earli
stage
play
role
prevent
infect
sar
patient
one
studi
sar
patient
report
one
patient
recov
receiv
antibacteri
treatment
alon
condit
patient
improv
comprehens
treatment
includ
antibiot
undisput
antibiot
agent
essenti
treatment
confirm
bacteri
infect
whether
antibiot
agent
use
treat
children
still
remain
controversi
issu
therefor
perform
rapid
review
assess
valu
antibiot
agent
children
provid
support
evid
rapid
advic
guidelin
manag
children
addit
intend
evalu
current
condit
use
antibiot
secondari
infect
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
valu
antibiot
agent
children
follow
seven
assess
current
condit
use
antibiot
bacteri
coinfect
patient
includ
case
seri
case
report
descript
studi
relat
report
inform
antibiot
use
bacteri
coinfect
howev
rule
studi
without
clear
descript
whether
antibiot
use
treat
routin
use
antibiot
surgeri
antibiot
use
eye
drop
assess
valu
antibiot
use
children
includ
studi
met
follow
criteria
type
studi
primarili
consid
type
studi
use
antibiot
treat
patient
fail
identifi
suffici
mani
studi
also
includ
studi
use
antibiot
treat
sar
mer
type
particip
studi
includ
patient
diagnos
sar
mer
necessari
without
restrict
age
race
gender
geograph
locat
set
includ
type
intervent
includ
studi
compar
outcom
patient
take
antibiot
agent
type
antibiot
limit
also
includ
case
seri
case
report
comprehens
treatment
antibiot
drug
studi
mention
antibiot
treatment
without
explain
specif
method
use
treatment
effect
exclud
type
outcom
primari
outcom
mortal
durat
hospit
durat
fever
secondari
outcom
includ
chest
xray
absorpt
relev
indic
mention
includ
studi
exclud
anim
studi
vitro
experi
studi
publish
english
chines
duplic
confer
abstract
comment
similar
document
elimin
duplic
two
review
perform
independ
search
two
step
describ
discrep
settl
discuss
consult
third
review
use
bibliograph
softwar
endnot
prior
formal
select
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
train
exercis
random
sampl
citat
conduct
ensur
reliabl
feasibl
select
suffici
agreement
select
method
reach
step
titl
abstract
screen
use
predefin
criteria
studi
categor
three
group
potenti
elig
exclud
unclear
step
fulltext
potenti
elig
unclear
studi
review
identifi
final
inclus
reason
exclus
inelig
studi
record
process
studi
select
document
use
prisma
flow
diagram
two
review
extract
data
independ
standard
data
collect
form
disagr
resolv
consensu
third
review
check
consist
accuraci
data
formal
extract
form
pilot
random
sampl
three
includ
studi
extract
form
final
counsel
clinician
data
extract
includ
basic
inform
titl
first
author
public
year
studi
design
sampl
size
particip
baselin
characterist
diseas
patient
detail
intervent
control
condit
outcom
dichotom
outcom
abstract
number
event
total
number
particip
group
continu
outcom
abstract
mean
standard
deviat
sd
number
total
particip
group
outcom
zero
event
report
exclud
analysi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
case
seri
case
report
use
antibiot
bacteri
coinfect
patient
extract
basic
inform
type
ratio
antibiot
bacteri
coinfect
appli
cochran
riskofbia
rob
tool
rct
newcastleottawa
scale
no
cohort
studi
casecontrol
studi
criteria
recommend
nation
institut
health
clinic
optim
nice
case
seri
assess
risk
bia
two
review
assess
risk
bia
independ
follow
overal
assess
principl
disagr
discuss
consensu
meet
use
tool
produc
risk
bia
summari
tabl
includ
item
judgement
support
judgement
assess
qualiti
case
seri
case
report
use
antibiot
bacteri
coinfect
patient
data
similar
enough
summar
meaning
way
would
conduct
metaanalysi
use
review
manag
would
use
fixedeffect
metaanalysi
combin
data
reason
assum
studi
evalu
underli
treatment
effect
trial
took
intervent
trial
popul
method
judg
suffici
similar
clinic
heterogen
suffici
enough
expect
underli
treatment
effect
differ
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
trial
statist
heterogen
detect
use
randomeffect
metaanalysi
produc
overal
summari
condit
averag
treatment
effect
across
trial
consid
clinic
meaning
qualit
synthesi
perform
signific
heterogen
exist
case
seri
case
report
use
antibiot
bacteri
coinfect
patient
describ
current
situat
two
review
jianjian
wang
yuyi
tang
assess
qualiti
evid
independ
use
grade
recommend
assess
develop
evalu
grade
approach
grade
approach
direct
evid
rct
begin
high
qualiti
evid
observ
studi
low
level
qualiti
downgrad
five
reason
studi
limit
consist
effect
imprecis
indirect
public
bia
upgrad
three
reason
larg
magnitud
effect
doserespons
relat
plausibl
confound
bias
order
reflect
extent
confid
estim
effect
correct
qualiti
evid
grade
high
moder
low
low
produc
summari
find
tabl
present
overal
qualiti
bodi
evid
outcom
use
gradepro
softwar
assess
qualiti
evid
case
seri
case
report
use
antibiot
bacteri
coinfect
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
public
health
emerg
intern
concern
situat
evolv
rapidli
studi
regist
order
speed
process
literatur
search
figur
yield
relev
record
studi
valu
use
antibiot
agent
includ
studi
sar
mer
duplic
applic
exclus
criteria
six
studi
includ
qualit
synthesi
studi
therefor
includ
studi
sar
mer
fulfil
inclus
criteria
six
includ
studi
publish
sampl
size
rang
total
particip
tabl
particip
six
studi
adult
studi
children
found
five
studi
investig
sar
patient
one
studi
enrol
patient
mer
due
signific
heterogen
conduct
qualit
synthesi
instead
metaanalysi
overview
qualiti
includ
studi
present
tabl
four
case
seri
moder
risk
score
one
case
seri
high
risk
score
cohort
studi
low
risk
score
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
mortal
main
outcom
studi
one
studi
sar
patient
took
cephalosporin
macrolid
broadspectrum
antibiot
risk
death
one
case
seri
sar
patient
show
risk
death
patient
use
macrolid
quinolon
beta
lactamas
separ
respect
anoth
case
seri
sar
patient
show
risk
death
use
antibiot
agent
patient
confirm
secondari
infect
one
case
seri
patient
use
broadspectrum
antibiot
first
two
day
anoth
case
seri
particip
use
combin
betalactam
macrolid
show
overal
risk
death
respect
mer
patient
differ
risk
death
patient
treat
without
macrolid
adjust
ci
one
studi
sar
patient
investig
durat
hospit
stay
patient
use
macrolid
quinolon
beta
lactamas
mean
durat
hospit
stay
day
respect
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
one
case
seri
investig
time
hospit
reach
normal
bodi
temperatur
sar
patient
patient
treat
macrolid
quinolon
beta
lactamas
averag
fever
durat
day
respect
one
studi
mer
patient
reveal
macrolid
therapi
associ
merscov
rna
clearanc
adjust
ci
p
studi
sar
qualiti
evid
mortal
durat
hospit
durat
fever
low
main
reason
risk
bia
studi
mer
qualiti
evid
rna
clearanc
mortal
low
tabl
identifi
studi
report
antibiot
use
bacteri
coinfect
four
studi
children
reveal
proport
use
antibiot
rang
tabl
commonli
use
type
meropenem
linezolid
howev
none
four
studi
mention
etiolog
find
twentynin
studi
adult
show
patient
receiv
antibiot
hospit
stay
commonli
use
type
adult
quinolon
especi
moxifloxacin
cephalosporin
macrolid
howev
patient
bacteri
coinfect
common
pathogen
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
gramneg
bacillu
acinetobact
baumannii
klebsiella
pneumonia
haemophilu
influenza
direct
evid
support
efficaci
antibiot
agent
children
high
proport
patient
treat
antibiot
despit
lack
etiolog
evid
current
evid
suggest
secondari
bacteri
infect
acinetobact
baumannii
klebsiella
pneumonia
may
occur
patient
antibiot
agent
wide
use
clinic
treatment
sar
evid
suggest
earli
use
antibiot
effect
clinic
outcom
use
broadspectrum
antibiot
increas
risk
dysbacteriosi
caus
nosocomi
infect
howev
bacteri
infect
identifi
ration
use
antibiot
agent
show
valid
result
reliev
symptom
reduc
leukocyt
count
use
antibiot
agent
one
import
clinic
question
relat
manag
children
current
guidelin
suggest
avoid
use
antibiot
agent
blindli
inappropri
use
confirm
secondari
bacteri
infect
meanwhil
guidelin
expert
consensu
statement
believ
use
antibiot
agent
could
taken
consider
glucocorticoid
treatment
patient
sever
critic
ill
extens
lesion
rang
larg
amount
airway
secret
systemat
review
nonsever
pneumonia
children
howev
found
evid
support
question
continu
use
antibiot
agent
children
nonsever
pneumonia
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
research
emphas
import
toxic
side
effect
drug
resist
antibiot
mani
studi
also
analyz
bacteri
type
drug
resist
secondari
bacteri
infect
sar
patient
secondari
infect
consid
import
risk
factor
mortal
sar
patient
first
systemat
review
aim
assess
applic
antibiot
agent
children
studi
summar
literatur
efficaci
safeti
antibiot
agent
treatment
patient
sar
mer
amount
qualiti
literatur
cover
systemat
review
howev
limit
review
mainli
cover
studi
treatment
adult
sar
mer
sinc
found
direct
evid
treatment
children
due
differ
patient
inclus
criteria
treatment
protocol
outcom
measur
among
differ
studi
unabl
carri
metaanalysi
therefor
highqual
clinic
trial
need
confirm
efficaci
antibiot
agent
children
addit
futur
studi
allow
suffici
followup
time
focu
advers
reaction
better
evalu
safeti
antibiot
agent
sinc
outbreak
public
health
emerg
order
complet
rapid
review
fast
possibl
review
regist
summari
found
direct
evid
support
efficaci
antibiot
agent
children
therefor
remain
unclear
whether
antibiot
agent
use
treat
children
rapid
review
show
benefit
antibiot
adult
infect
sar
mer
question
absenc
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
bacteri
coinfect
therefor
recommend
use
antibiot
agent
children
evid
bacteri
coinfect
thank
jann
estil
institut
global
health
univers
geneva
provid
guidanc
comment
review
thank
author
wonder
collabor
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
